GFAP and Alzheimer disease: Quantification of GFAP in the hippocampus revealed that there was a 1.29 FC reduction in astrocyte reactivity in aged 3xTg-AD iPSC-NPCs treated mice compared to 3xTg-AD PBS animals (n = 7–8/group; Figure 7g; p < 0.01).